Speakers: Title: Peter Ratsep, Ph.D. (Technical Support Supervisor) and Sarah Braseth (Regional Manager), Shimadzu Scientific Instruments NJ office
peter and sarah
When: Wed, Oct 20, 2021 9:00 AM - 10:00 AM PDT
Event Overview: Many laboratories today are faced with the challenge of running multiple different analyses on the same sample. This challenge can present itself when there is an increase in sample complexity, additional sample regulations and requirements that must be met, when sampling is done at different time markers, when you are scouting for the right method settings, or if you are doing general API analysis to meet different USP requirements. The Shimadzu Nexera Dual Injection (U)HPLC system is equipped with two injection ports (independent flow paths) which allows two analyses to be run simultaneously on a single instrument, potentially decreasing your analysis time by 50%. This webinar will highlight specific applications of simultaneous analyses done on one sample with one (U)HPLC. In addition, this webinar will also explain how the two sets of data are then integrated into a single data file simplifying data management and ensuring data integrity.
Key learning Objectives:
• Understanding the advantages of a dual injection system
• Learn a novel approach to address efficiency when running a single sample under multiple different analyses conditions
• Maintaining data integrity and data tracking by combining data and method files from multiple runs
Who Should Attend:
• Method developers in pharmaceutical, foods and cosmetics, chemical, environmental, agrichemical, contract research organization, university and governmental laboratories.
• Scientists working in an HPLC laboratory looking to increase throughput and efficiency with their workflows
Speakers: Tony Edge, Ph.D., Site Director (Product R&D), Avantor Hichrom
Tony Edge
When: Wed, Nov 3, 2021 9:00 AM - 10:00 AM PDT
Event Overview: In the summer of 2018, the pharmaceutical landscape for the manufacture of small molecules has changed forever with the discovery of a genotoxic compound called N-nitrosodimethylamine (NDMA) in a batch of Valsartan manufactured by Zhejiang Huahai Pharmaceutical in China. Valsartan is a prescription only drug to treat high blood pressure and heart failure, which is a selective angiotensin II receptor blocker (ARB) used to dilates blood vessels. In routine analysis, the QC chemists found that there were approaching 60 ppm of NDMA, which is high enough to cause one extra case of cancer in 500 patients. On 5th July of 2018, the European Medical Agency (EMA) gave notice to recall selected batches of Valsartan with immediate effect. Since 2018, NDMA and other nitrosamines have been detected at alerted levels in a range of different pharmaceuticals.
This webinar will look at the chronological development of the story and how nitrosamines have caused the pharmaceutical industry to re-evaluate their manufacturing procedures. It will look at the synthetic pathways that can generate these genotoxins and the regulatory landscape that has evolved as a consequence of the initial findings. We will then discuss the development of a series of applications that will allow for the determination of nitrosamines that have been identified as genotoxins by the US Food and Drug Administration (FDA) to monitor, initially showing how to perform a separation of these compounds from the active pharmaceutical ingredient (API) and then looking at how mass spectrometry can be applied to the analysis to ensure that the required detection limits can be reached.
Key learning Objectives:
• Learn the importance of testing for NDMA concentrations in pharmaceuticals
• Understand the regulatory landscape that has evolved to deal with this range of genotoxins such as nitrosamines impurities
• Review examples of nitrosamine analysis
Speaker: Stephanie A. Schuster, Senior Technical Support Scientist, Advanced Materials Technology, Inc.
When: Wed, Sep 22, 2021 9:00 AM - 10:00 AM PDT
About the Speaker: Dr. Schuster earned her B.A. at La Salle University, and her Ph.D. under the guidance of Prof. Joe P. Foley at Drexel University. After graduation, Stephanie spent nine months at Atlantic Diagnostic Laboratories, a combined clinical and forensic testing laboratory. She joined Advanced Materials Technology, Inc. (AMT) located in Wilmington, DE in June 2009 as a research scientist working with Dr. Jack Kirkland, providing contributions to the commercial development of products designed specifically for the separation of peptides and proteins. Most recently, as part of the Technical Support team at AMT, Stephanie has been providing customers support in optimizing and trouble-shooting their applications. Stephanie has several peer-reviewed articles and is a member of the Chromatography Forum of the Delaware Valley (CFDV) and the American Society of Mass Spectrometry (ASMS).
Abstract: Monoclonal antibodies (mAbs) continue to be among the top selling pharmaceuticals because they are such effective therapeutics. Not only are mAbs used for disease treatment, but they are also used for research and diagnostic purposes. Characterization of mAbs is a critical step in their development. Intact analysis may be completed by LC-UV or LC-MS methods using Fused-Core particle columns. Additionally, post-translational modifications (PTMs) of mAbs must be characterized and controlled. Many PTMs are polar by their nature, including glycosylation, deamidation, and oxidation. These types of polar modifications lend themselves to analysis via hydrophilic interaction liquid chromatography (HILIC) since they can be better resolved than with reversed-phase chromatography. Examples of glycosylation, deamidation, and oxidation of different mAbs will be demonstrated using LCMS under HILIC conditions.
 Speaker: Yichen Wang, Specialist of Ion Chromatography, Product Manager of SHINE Ion Chromatography
Yichen Wang
When: Wed, Aug 25, 2021 9:00 AM - 10:00 AM PDT
Abstract: Ion chromatography (IC), a well-established form of liquid chromatography, uses ion-exchange resins to separate cations or anions. There are two types of IC, anion-exchange and cation-exchange. Equipped with different detectors, IC could be a powerful separation technique to address challenging analytical tasks. For example, IC can detect carbohydrate in dairy products using electrochemical detector. Recently, IC has been extensively used for purification and characterization of biopharmaceutical drugs such as monoclonal antibody (mAb) and adeno-associated virus (AAV). Trace analysis of elemental impurities with low detection limit can be achieved with combination of ICP-MS/MS. It is possible to detect hexavalent ions such as chromium at ppt levels in toys.
Due to its excellent sensitivity, selectivity, and fast speed, IC has proven to be a very useful technique for determination of both organic and inorganic ions (in particular non-metal ions) and applied in various fields such as food, environmental, material and pharmaceutical analyses. To explore the growing interest of IC in pharmaceutical industry, this seminar will start with a brief introduction of IC principle, operation, and instrumentation followed by its application in analysis of raw materials, intermediates, drug substance, excipients, and finished drug products based on pharmacopeia standards from different countries.
Key Learning Objectives:
• Brief introduction of IC Principle, operation and instrumentation
• Application of IC in pharmaceutical drug analysis
Who Should Attend:
• IC users and method developers in pharmaceutical, chemical, clinical, environmental, agrichemical, contract research organizations, universities, and governmental laboratories.

Speaker: Chris Pohl, Vice President, Research & Development, Chromatography Chemistry, Thermo Fisher Scientific

Chris Pohl


When: Wed, Aug 4, 2021 9:00 AM - 10:00 AM PDT

Registration link: https://register.gotowebinar.com/register/7467419398288012048

Abstract: Since the approval of the first therapeutic monoclonal antibody, muromonab-CD3, in 1986, the field of monoclonal antibody therapeutics has exploded into a variety of monoclonal antibody-based therapeutics, such as bi-specifics and antibody drug conjugates (ADCs). Unlike small molecule drugs whose production can be tightly controlled, production of biotherapeutics using biological vehicles creates its own challenges in not only producing a pure product but also a properly conformed one. The need to characterize product quality attributes continues to be of critical importance in ensuring the efficacy and safety of biotherapeutics. Since Dionex released the ProPac WCX-10 in 1998 for charge variant analysis, the team in Sunnyvale, led by Chris Pohl (VP R&D), has continued to develop new generations of columns focused on large molecule chromatography, based on feedback from the Biopharma community to address regulatory approval requirements. Charge variants, oxidation, deamidation, and drug to antibody ratios are just a few of the analysis that have become commonplace, and Thermo Fisher Scientific has led the way in offering chromatography solutions for biotherapeutics characterization, from ProPac WCX-10 to ProPac ELITE and CX-1 buffers. Join us to learn what we’ve learned from the biopharma community during the past 23 years.


Key Learning Objectives: • HPLC based techniques for characterization of monoclonal antibody-based biotherapeutics

Who Should Attend: • Method developers for UHPLC and HPLC methods supporting monoclonal antibody development • Method QC chemists who use these columns (ProPac WCX-10, ProPac ELITE, etc.) everyday